Angiomyolipoma

An angiomyolipoma is a non-cancerous (benign) growth in your kidney. It's made up of three types of tissue: blood vessels, fat, and smooth muscle. It's often linked to a condition called tuberous sclerosis.

Condition

What people with Angiomyolipoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Everolimus for Angiomyolipoma?

NameHow it went

About Angiomyolipoma

What It Is

An angiomyolipoma is a tumor made of three kinds of tissue: fat, smooth muscle and abnormal blood vessels. It almost always grows in the kidney, and the usual form is benign, meaning it is not cancer and does not spread. Most angiomyolipomas cause no symptoms and are found by chance on an ultrasound or CT scan done for another reason. The main concern is bleeding rather than cancer. The tumor's blood vessels are fragile, and a larger tumor can bleed into or around the kidney, sometimes heavily. Large or numerous tumors can also gradually reduce kidney function. Angiomyolipomas appear in two broad settings. Most are sporadic: a single, small, slow-growing tumor in one kidney, usually found in middle age and about twice as often in women. Others occur with tuberous sclerosis complex (TSC), a genetic condition that causes noncancerous growths in many organs, or with lymphangioleiomyomatosis (LAM), a rare lung disease that mainly affects women. In these conditions the tumors tend to be multiple, affect both kidneys, appear at a younger age and grow faster. A rare subtype, epithelioid angiomyolipoma, can behave like a cancer. Angiomyolipomas occasionally form in the liver, but this page focuses on the kidney.

Causes & Risk Factors

Researchers do not know why a sporadic angiomyolipoma forms, and no lifestyle cause has been identified. Being female is the clearest pattern, with women affected about twice as often as men. Roughly a third to a half of angiomyolipomas are linked to TSC or LAM. In TSC, an inherited or new change in one of two genes switches on a cell growth signal called mTOR, which drives tumor growth in the kidneys and elsewhere. Up to 80% of people with TSC develop kidney angiomyolipomas. Several tumors in both kidneys, especially in a younger person, can be a clue to TSC. Separate from what causes the tumor are factors that make bleeding more likely: larger size, faster growth, bulging weak spots in the tumor's blood vessels (aneurysms) wider than about 5 millimeters, pregnancy, TSC, blood-thinning medicines (anticoagulants) and injury to the area.

How It's Diagnosed

Because the tumor contains fat, it usually has a recognizable appearance on imaging. A CT scan, especially one taken without contrast dye, can show fat inside a kidney mass, which strongly suggests angiomyolipoma. Ultrasound often finds the tumor first, and MRI helps when the picture is unclear. A few kidney cancers and other growths can also contain fat, so radiologists look at the tumor's other features as well. Some angiomyolipomas contain very little fat and can look like kidney cancer on scans. This is more common in TSC, where MRI is the preferred test. When imaging cannot settle the question, a needle biopsy can confirm the diagnosis; its result matches the final diagnosis in about 93% of cases. Imaging also measures the tumor, looks for aneurysms inside it and checks the other kidney. Blood tests of kidney function and blood pressure measurements are part of the baseline assessment, particularly when there are several tumors or TSC.

Treatment Options

Treatment aims to prevent bleeding and protect kidney function, not to remove every tumor. For most small tumors that cause no symptoms, the usual approach is active surveillance: repeat imaging, often at 6 and 12 months and then yearly, to see whether the tumor changes. Most sporadic tumors grow very slowly or not at all. Treatment is considered when a tumor causes pain or bleeding, grows quickly, contains aneurysms wider than about 5 millimeters, cannot be distinguished from cancer, or is found in a woman who may become pregnant. Size alone is a debated trigger. The traditional cutoff of 4 centimeters (about 1.5 inches) flags many tumors that would never bleed, so doctors weigh size together with these other factors. Selective arterial embolization is the most common procedure. A radiologist guides a thin tube through an artery to the kidney and blocks the vessels feeding the tumor so it shrinks. It avoids open surgery and is also the main way to stop active bleeding. Many people have a few days of fever and side pain afterward, and about 1 in 5 eventually need a repeat procedure or surgery. Kidney-sparing surgery (partial nephrectomy) removes the tumor while keeping the rest of the kidney; it is more invasive but less likely to need repeating. Thermal ablation, which destroys the tumor with heat or cold, has been tried in only small numbers of people. Removing the whole kidney is avoided where possible, especially in TSC, because it raises the risk of kidney failure later. Epithelioid angiomyolipoma is treated like kidney cancer. For angiomyolipomas linked to TSC, everolimus (Afinitor) is the recommended first choice when a tumor is larger than 3 centimeters and growing. It is a daily pill that blocks the mTOR growth signal. In its main trial, about 4 in 10 people saw their tumors shrink by at least half, compared with none on a placebo, and tumors were much slower to grow. It controls the tumors rather than cures them, so it is taken for as long as it keeps working and is tolerated. Mouth sores are the most common side effect; it also raises infection risk, needs regular blood tests and should not be used during pregnancy. A benefit for sporadic angiomyolipoma has not been established.

What to Expect

For most people with a single small sporadic tumor, angiomyolipoma has little effect on daily life. Many tumors stay the same size for years, and the main commitment is periodic scans and checkups. Serious bleeding is uncommon in tumors that are monitored, but it is the reason follow-up matters. In TSC, angiomyolipomas are a lifelong part of the condition. Follow-up usually includes MRI of the kidneys every 1 to 3 years and yearly checks of kidney function and blood pressure, since high blood pressure and chronic kidney disease are more common and can begin earlier than in the general population. Treatment decisions often happen over many years as tumors change. Pregnancy deserves planning. Case reports describe angiomyolipomas growing and bleeding during pregnancy, although no large studies have tracked how often this happens. Some doctors recommend treating larger tumors before a planned pregnancy. It also helps to make sure any clinician starting a blood thinner knows about the tumor.

When to Seek Help

If an angiomyolipoma was found by chance, arrange a visit with a urologist or your primary clinician to plan monitoring, and keep scheduled scans even when you feel well. Contact your care team promptly for visible blood in your urine or new, persistent pain in your side or back. Sudden, severe pain in the side, back or abdomen, especially with lightheadedness, fainting or a racing heartbeat, can mean the tumor is bleeding heavily. Call 911 or get emergency care right away.

Questions to Ask Your Doctor

  1. 1.Does my tumor look like a typical angiomyolipoma, or is more testing needed to rule out cancer?
  2. 2.Given its size, growth and blood vessels, how high is my risk of bleeding, and how often should it be scanned?
  3. 3.Would embolization, surgery or medication help me now, or is monitoring the better choice?
  4. 4.Is there any reason to check for tuberous sclerosis complex in my case?
  5. 5.How should a future pregnancy or a new blood-thinning medicine change my plan?

Last reviewed • Oct 2026

Educational content, not medical advice.